RNA (Atrium Therapeutics) Inventories, Finished Goods: $0.00 Mil (As of Mar. 2026)


RNA Atrium Therapeutics Inc RNA
12 GF Score
Price $13.15
! 1 Warning Sign
View Full Analysis

What is Atrium Therapeutics Inventories, Finished Goods?

Atrium Therapeutics RNA +3.21% 12 Inventories, Finished Goods is $0.00 Mil as of Mar. 2026. GuruFocus rates RNA with a GF Score™ of 12/100. The stock has 1 warning sign investors should review.

Atrium Therapeutics Inventories, Finished Goods Historical Data

* Premium members only.

The historical data trend for Atrium Therapeutics's Inventories, Finished Goods can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Atrium Therapeutics Inventories, Finished Goods Chart

Atrium Therapeutics Annual Data
Trend Dec23 Dec24 Dec25
Inventories, Finished Goods
0.00 0.00 0.00

Atrium Therapeutics Quarterly Data
Dec23 Dec24 Mar25 Sep25 Dec25 Mar26
Inventories, Finished Goods Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00
RNA
12GF Score
Atrium Therapeutics Inc RNA
Inventories, Finished Goods is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Atrium Therapeutics Inventories, Finished Goods Calculation

The products in a manufacturer's inventory that are completed and are waiting to be sold.

What does a Inventories, Finished Goods of $0.00 Mil mean?
Atrium Therapeutics (RNA) has a Inventories, Finished Goods of $0.00 Mil as of Mar. 2026. Finished goods are inventory items that are complete and ready to be sold. View historical data on Atrium Therapeutics and its competitors.
Is Atrium Therapeutics' Inventories, Finished Goods too high?
Atrium Therapeutics' current Inventories, Finished Goods is $0.00 Mil. Overall, Atrium Therapeutics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Atrium Therapeutics' Inventories, Finished Goods compare to CNTN and QTTB?
Atrium Therapeutics' Inventories, Finished Goods of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Inventories, Finished Goods for a Biotechnology company?
A good Inventories, Finished Goods depends on the Biotechnology industry context. However, Inventories, Finished Goods should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Inventories, Finished Goods mean?
A high Inventories, Finished Goods can signal that a stock is expensive relative to its fundamentals. Finished goods are inventory items that are complete and ready to be sold. View historical data on Atrium Therapeutics and its competitors. Atrium Therapeutics's current Inventories, Finished Goods is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Atrium Therapeutics stock overvalued right now?
Atrium Therapeutics (RNA) has a current Inventories, Finished Goods of $0.00 Mil. The current Inventories, Finished Goods is $0.00 Mil. Atrium Therapeutics' overall GF Score™ is 12/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Inventories, Finished Goods calculated?
Inventories, Finished Goods is calculated from a company's financial statements. For Atrium Therapeutics (RNA), the current Inventories, Finished Goods is $0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Atrium Therapeutics Business Description

Address 10578 Science Center Drive, Suite 125, San Diego, CA, USA, 92121
Atrium Therapeutics Inc is a biopharmaceutical firm focused on developing RNA-based therapeutics for cardiac conditions, including cardiomyopathies. Its platform technology is designed to enable targeted delivery of RNA therapeutics to heart tissue by combining ligand-based targeting approaches with oligonucleotide-based therapies. The company's development pipeline includes programs targeting genetically associated forms of cardiomyopathy, specifically involving the PRKAG2 and PLN genes.
12GF Score

Get the complete analysis for RNA

Inventories, Finished Goods is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$13.15
Price